Quest PharmaTech Past Earnings Performance
Past criteria checks 0/6
Quest PharmaTech's earnings have been declining at an average annual rate of -38.5%, while the Biotechs industry saw earnings growing at 19.2% annually.
Key information
-38.5%
Earnings growth rate
-38.5%
EPS growth rate
| Biotechs Industry Growth | 51.1% |
| Revenue growth rate | n/a |
| Return on equity | -12.5% |
| Net Margin | n/a |
| Last Earnings Update | 31 Jul 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Quest PharmaTech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jul 24 | 0 | -3 | 1 | 0 |
| 30 Apr 24 | 0 | -4 | 1 | 1 |
| 31 Jan 24 | 0 | -3 | 1 | 0 |
| 31 Oct 23 | 0 | -8 | 0 | 1 |
| 31 Jul 23 | 0 | -64 | 1 | 1 |
| 30 Apr 23 | 0 | -64 | 1 | 0 |
| 31 Jan 23 | 0 | -65 | 1 | 0 |
| 31 Oct 22 | 0 | -78 | 1 | 0 |
| 31 Jul 22 | 0 | -87 | 1 | 0 |
| 30 Apr 22 | 0 | -86 | 1 | 0 |
| 31 Jan 22 | 0 | -85 | 1 | 0 |
| 31 Oct 21 | 0 | 68 | 1 | 0 |
| 31 Jul 21 | 0 | 81 | 1 | 0 |
| 30 Apr 21 | 0 | 83 | 1 | 0 |
| 31 Jan 21 | 0 | 190 | 1 | 0 |
| 31 Oct 20 | 0 | 111 | 1 | 4 |
| 31 Jul 20 | 0 | 106 | 2 | 7 |
| 30 Apr 20 | 0 | 102 | 2 | 9 |
| 31 Jan 20 | 0 | -6 | 2 | 11 |
| 31 Oct 19 | 0 | -5 | 2 | 8 |
| 31 Jul 19 | 0 | -5 | 3 | 7 |
| 30 Apr 19 | 0 | -5 | 3 | 6 |
| 31 Jan 19 | 0 | -4 | 3 | 6 |
| 31 Oct 18 | 0 | -5 | 3 | 6 |
| 31 Jul 18 | 0 | -6 | 2 | 7 |
| 30 Apr 18 | 0 | -5 | 2 | 6 |
| 31 Jan 18 | 0 | -5 | 2 | 5 |
| 31 Oct 17 | 0 | -3 | 2 | 4 |
| 31 Jul 17 | 0 | -3 | 3 | 3 |
| 30 Apr 17 | 0 | -3 | 3 | 3 |
| 31 Jan 17 | 0 | -2 | 2 | 2 |
| 31 Oct 16 | 0 | -6 | 2 | 2 |
| 31 Jul 16 | 0 | -5 | 1 | 2 |
| 30 Apr 16 | 0 | -5 | 1 | 1 |
| 31 Jan 16 | 0 | -5 | 1 | 1 |
| 31 Oct 15 | 0 | -2 | 1 | 1 |
| 31 Jul 15 | 0 | -2 | 1 | 1 |
| 30 Apr 15 | 0 | -2 | 1 | 2 |
| 31 Jan 15 | 0 | -2 | 1 | 2 |
| 31 Oct 14 | 0 | 0 | 1 | 1 |
| 31 Jul 14 | 0 | 0 | 1 | 1 |
| 30 Apr 14 | 0 | 0 | 1 | 1 |
Quality Earnings: QPT is currently unprofitable.
Growing Profit Margin: QPT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: QPT is unprofitable, and losses have increased over the past 5 years at a rate of 38.5% per year.
Accelerating Growth: Unable to compare QPT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: QPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: QPT has a negative Return on Equity (-12.52%), as it is currently unprofitable.